Potential breakthrough for diabetes sufferers
Wednesday, 17 December, 2003
Sufferers of type-two diabetes may soon be able to inhale rather than inject their insulin thanks to Melbourne researchers who have re-engineered the insulin molecule.
The molecule, engineered by Melbourne biotech company Eiffel Technologies, has been reduced in size by a factor of 1000 to significantly smaller than one-millionth of a metre, meaning the molecule can be inhaled.
Eiffel Technologies used super critical fluid technology to engineer the molecule - the same technology used to extract the caffeine from coffee beans without affecting their taste or smell.
In independent trials on rats at Deakin University, the molecule was quicker and lasted for a longer period of time. The speed element could be important in diabetic emergencies.
AXT to distribute NT-MDT atomic force microscopes
Scientific equipment supplier AXT has announced a partnership with atomic force microscope (AFM)...
Epigenetic patterns differentiate triple-negative breast cancers
Australian researchers have identified a new method that could help tell the difference between...
Combined effect of pollutants studied in the Arctic
Researchers from the Fram Centre in Norway are conducting studies in Arctic waters to determine...
